Tuesday, May 24, 2022
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Dr Reddys Collaborates With Four Pharma Companies For Molnupiravir Trial

Dr Reddy’s collaborates with four pharma companies for molnupiravir trial

By Telangana Today
Published: Published Date - 05:03 PM, Tue - 29 June 21
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India

Hyderabad: Hyderabad-based Dr Reddy’s Laboratories has collaborated with other pharma companies such as Cipla, Emcure Pharmaceuticals, Sun Pharmaceutical Industries and Torrent Pharmaceuticals for the clinical trial of the investigational oral anti-viral drug molnupiravir for the treatment of mild Covid-19 in an outpatient setting in India.

Between March and April this year, these five pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharp Dohme (MSD) to manufacture and supply molnupiravir to India and over 100 low and middle-income countries (LMICs).

The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India.

As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy’s in its clinical trial.

Following the clinical trial protocol approval given by the Drugs Controller General of India (DCGI), the clinical trial will be conducted for the treatment of mild Covid-19 in an outpatient setting. The trial is expected to take place between June and September this year across India with the recruitment of 1,200 patients.

Such collaboration for a clinical trial is a first-of-its-kind within the Indian pharma industry and will aim to investigate yet another line of treatment in the collective fight against the Covid-19 pandemic. On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply molnupiravir for the treatment of Covid-19 in India.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. It is presently being studied by MSD, through a collaboration with Ridgeback Biotherapeutics, in a phase III trial for the treatment of non-hospitalised patients with confirmed Covid-19 globally.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • Covid-19
  • Dr Reddy’s Laboratories
  • Dr.Reddy's
  • Molnupiravir

Related News

  • India logs 1,675 Covid cases in a day, 31 deaths

  • Saudi Arabia bans citizens from travelling to 16 nations, including India

  • India records 2,022 new COVID-19 infections, 46 fatalities

  • India announces squad for fifth test against England, Pujara returns after successful county stint

  • India records 2,226 new COVID-19 infections, 65 fatalities

  • ‘Developing infra holds key to success of medicine from sky’

Latest News

  • Telangana: Fruit vendor killed in a road mishap

    10 mins ago
  • Drones banned in Hyderabad in view of PM Modi’s visit

    29 mins ago
  • Samantha, Vijay injured after vehicle falls into deep water during shoot in Kashmir

    36 mins ago
  • Three held with cocaine in Hyderabad

    45 mins ago
  • Aamir Khan accepts offer from Rajasthan Royals, wants to join team next season

    1 hour ago
  • ‘Jug Jugg Jeeyo’ lands in plagiarism controversy

    1 hour ago
  • TSRTC to arrange battery vehicle rides for passengers at Secunderabad Railway Station

    1 hour ago
  • Influencer Tushar Kamble wins everyone with his exceptional content on Instagram

    1 hour ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam